Healthcare Providers and Services
Company Overview of Alliance Healthcare Deutschland AG
Alliance Healthcare Deutschland AG engages in the wholesale trade of pharmaceutical products to pharmacies and hospitals in Germany and internationally. The company also offers logistics concepts and services for healthcare and pharmaceutical industries; engages in the design and implementation of integrated marketing, distribution, and logistics services for suppliers of health, cosmetics, and care products; and provides inventory and accounting, warehousing and distribution, complaint processing, return management, and hotline services. In addition, it provides market research services to the pharmaceutical manufacturers, pharmaceutical wholesale trade customers, and information service pr...
Frankfurt am Main, 60486
Key Executives for Alliance Healthcare Deutschland AG
Chairman of the Executive Board and Chairman of Executive Committee
Head of Account System & Finances and Member of Executive Committee
Personnel & Operations Director
Member of The Executive Board and Labour Relations Director
Commerce & Services Director
Compensation as of Fiscal Year 2014.
Alliance Healthcare Deutschland AG Key Developments
Andreae-Noris Zahn AG Reports Consolidated Earnings Results for the Nine Months Ended December 31, 2012
Feb 16 13
Andreae-Noris Zahn AG reported consolidated earnings results for the nine months ended December 31, 2012. Sales revenues increased against the comparative prior year period by EUR 10.0 million or 0.3% from EUR 3,317.3 million to EUR 3,327.3 million. Lower other operating income, which was impacted comparatively by the release of valuation allowances in the prior year lower personnel expenses, as well as lower other operating expenses due to cost savings, resulted in earnings before interest and taxes (EBIT) of EUR 46.0 million which were EUR 20.9 million above the result of the comparative prior year period of EUR 25.1 million. However, the impact of restructuring costs in the prior year must be taken into account in this comparison. The financial result improved from loss of EUR 20.4 million to loss of EUR 11.2 million. This is attributable to a decline in interest expenses in connection with the refinancing of the KfW loan and the repayment of the promissory note loans, as well as lower dividend payments to minority shareholders with put options. Overall, earnings before taxes (EBT) rose by EUR 30.1 million from EUR 4.7 million to EUR 34.8 million. With tax expenses of EUR 9.3 million, the consolidated profit increased by EUR 22.2 million to EUR 25.5 million against EUR 3.3 million last year. The earnings per share (both diluted and undiluted) amounted to EUR 2.39 compared with EUR 0.32 during the prior year period. In accordance with the requirements of IAS 8.29, the adjustment in reporting has had an effect on the corresponding comparative period insofar as the cash flow from operating activities improved by EUR 9.6 million to cash used in operating activities of EUR 53.3 million. Mainly due to seasonally higher inventories, the cash used in operating activities amounted to EUR 13.4 million against EUR 53.3 million last year. The cash flow used in investment activities amounted to EUR 6.8 million against EUR 11.0 million last year. This related primarily to investments in buildings and the car fleet.
Andreae-Noris Zahn AG, Special/Extraordinary Shareholders Meeting, Dec 18, 2012
Oct 27 12
Andreae-Noris Zahn AG, Special/Extraordinary Shareholders Meeting, Dec 18, 2012.
Andreae-Noris Zahn AG Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2012; Reaffirms Earnings Guidance for the Fiscal 2013
Aug 14 12
Andreae-Noris Zahn AG reported unaudited consolidated earnings results for the first quarter ended June 30, 2012. For the quarter, the group's consolidated sales revenues increased versus the comparative prior year period by EUR 26.3 million, from EUR 1,080.0 million to EUR 1,106.3 million. This corresponds to a 2.4% rise. Lower other operating income due to the discontinuation of valuation effects, higher personnel expenses as well as lower operating expenses due to cost savings resulted in earnings before interest and taxes (EBIT) of EUR 18.3 million, that means EUR 5.4 million higher than during the comparative period (EUR 12.9 million). The financial result improved by EUR 3.1 million and amounted to EUR 2.1 million from EUR 5.2 million in a year ago. This was mainly attributable to a decline in interest expenses versus the comparative period, in connection with the refinancing of the KfW loan and the promissory note loans. Earnings before taxes (EBT) rose altogether from EUR 7.7 million by EUR 8.5 million to EUR 16.2 million. Consolidated result rose by EUR 6.2 million to EUR 12.4 million from EUR 6.2 million. Earnings per share (both diluted and undiluted) amounted to EUR 1.16 after EUR 0.59 during the comparative period. Mainly due to seasonally higher inventories, the cash flow from operating activities amounted to EUR 0.5 million during the reporting period. Consequently, it was EUR 29.5 million better than during the comparative period against EUR 29.0 million.
The assessment of the essential opportunities and risks has not changed compared to the last consolidated management report. The result forecast for the full financial year 2013 remains likewise unchanged.
Similar Private Companies By Industry
Recent Private Companies Transactions